Advanced search
Publication Cover
Blood and Lymphatic Cancer: Targets and Therapy Volume 4, 2014 - Issue
Submit an article Journal homepage
84
Views
0
CrossRef citations to date
0
Altmetric
Original Research

The absolute lymphocyte/monocyte ratio recovery during ABVD treatment cycles is not significantly impacted by the use of myeloid growth factors and predicts clinical outcomes in classical Hodgkin lymphoma regardless of their use

Gregory P Kaufman1 Department of Internal MedicineCorrespondence[email protected]
,
Kay M Ristow1 Department of Internal Medicine;2 Division of Hematology, Mayo Clinic, Rochester, MN, USA
,
Svetomir N Markovic1 Department of Internal Medicine;2 Division of Hematology, Mayo Clinic, Rochester, MN, USA
&
Luis F Porrata1 Department of Internal Medicine;2 Division of Hematology, Mayo Clinic, Rochester, MN, USA
Pages 39-44 | Published online: 23 Jul 2014

References

  • Diehl V, Stein H, Hummel M, Zollinger R, Connors JM. Hodgkin’s lymphoma: biology and treatment strategies for primary, refractory, and relapsed disease. Hematology Am Soc Hematol Educ Program. 2003:225–247.
  • Thompson CA, Mauck K, Havyer R, Bhagra A, Kalsi H, Hayes SN. Care of the Adult Hodgkin Lymphoma Survivor. Am J Med. 2011; 124(12):1106–1112.
  • Porrata LF, Ristow K, Colgan JP, et al. Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin’s lymphoma. Haematologica. 2012;97(2):262–269.
  • Koh YW, Kang HJ, Park C, et al. The Ratio of the Absolute Lymphocyte Count to the Absolute Monocyte Count Is Associated with Prognosis in Hodgkin’s Lymphoma: Correlation with Tumor-Associated Macrophages. Oncologist. 2012;17(6):871–880.
  • Steidl C, Lee T, Shah SP, et al. Tumor-Associated macrophages and Survival in Classical Hodgkin’s Lymphoma. N Engl J Med. 2010;362(10):875–885.
  • Moccia AA, Donaldson J, Chhanabhai M, et al. International Prognostic Score in Advanced-Stage Hodgkin’s Lymphoma: Altered Utility in the Modern Era. J Clin Oncol. 2012;30(27):3383–3388.
  • Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood. 2006;107(1):52–59.
  • Porrata LF, Ristow KM, Habermann TM, et al. Peripheral blood absolute lymphocyte/monocyte ratio recovery during ABVD treatment cycles predicts clinical outcomes in classical Hodgkin lymphoma. Blood Cancer J. 2013;3:e110.
  • Böhme M, Schmidt D, Radke J, Morenz J, Weise W. Effect of granulocyte colony stimulating factor (G-CSF) on peripheral blood leukocytes and lymphocytes in patients with chemotherapy-induced leukopenia. Geburtshilfe Frauenheilkd. 1994;54(12):670–674. German.
  • Lyman GH, Kuderer NM, Crawford J, et al. Predicting Individual Risk of Neutropenic Complications in Patients Receiving Cancer Chemotherapy. Cancer. 2011;117(9):1917–1927.
  • National Comprehensive Cancer Network. Myeloid Growth Factors (Version 1.2014). http://www.nccn.org/professionals/physician_gls/pdf/myeloid_growth.pdf. Accessed March 14, 2014.
  • Younes A, Fayad L, Romaquera J, Pro B, Goy A, Wang M. Safety and efficacy of once-per-cycle pegfilgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphoma. Eur J Cancer. 2006;42(17):2976–2981.
  • Evens AM, Cilley J, Ortiz T, et al. G-CSF in not necessary to maintain over 99% dose-intensity with ABVD in the treatment of Hodgkin lymphoma: low toxicity and excellent outcomes in a 10-year analysis. Br J Haematol. 2007;137(6):545–552.
  • Boleti E, Mead GM. ABVD for Hodgkin’s lymphoma: full-dose chemotherapy without dose reductions or growth factors. Ann Oncol. 2007;18(2):376–380.
  • Saxman SB, Nichols CR, Einhorn LH. Pulmonary Toxicity in Patients with Advanced-Stage Germ Cell Tumors Receiving Bleomycin with and Without Granulocyte Colony Stimulating Factor. Chest. 1997;111(3):657–660.
  • Martin WG, Ristow KM, Habermann TM, Colgan JP, Witzig TE, Ansell SM. Bleomycin Pulmonary Toxicity Has a Negative Impact on the Outcome of Patients With Hodgkin’s Lymphoma. J Clin Oncol. 2005;23(30):7614–7620.
  • Cox CJ, Habermann TM, Payne BA, Klee GG, Pierre RV. Evaluation of the Coulter counter model S-Plus IV. Am J Clin Pathol. 1985;84(3):297–306.
  • Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin disease. International Prognostic Factors Project on Advanced Hodgkin’s Disease. N Engl J Med. 1998;339(21):1506–1514.
  • Ösby E, Hagberg H, Kvaløy S, et al. CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial. Blood. 2003;101(10):3840–3848.
  • Porrata LF, Ristow K, Habermann TM, et al. Absolute monocyte/lymphocyte count prognostic score is independent of immunohistochemically determined cell of origin in predicting survival in diffuse large B-cell lymphoma. Leuk Lymphoma. 2012;53(11):2159–2165.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.